From: Modelling imperfect adherence to HIV induction therapy
FDA-approved combination | Number of drug holidays (theoretical) | Length of each holiday (days) | Minimum subsequent therapy (days) | ||
---|---|---|---|---|---|
ABC* | 3TC | NVP | 16 | 3 | 7 |
ABC* | 3TC | EFV | 16 | 3 | 7 |
TDF | 3TC* | EFV | 14 | 3.5 | 8.5 |
ddI | 3TC* | EFV | 14 | 3.5 | 8.5 |
d4T* | 3TC | EFV | 50 | 1 | 2.5 |
d4T* | 3TC | NVP | 50 | 1 | 2.5 |
ddI* | FTC | EFV | 13 | 5 | 7.5 |
TDF | FTC* | EFV | 7 | 6 | 17 |
TDF | FTC | NVP* | 9 | 5 | 12.5 |
ZDV* | 3TC | ABC | 44 | 1.33 | 2.66 |
ZDV* | 3TC | EFV | 44 | 1.33 | 2.66 |
ZDV* | 3TC | NVP | 44 | 1.33 | 2.66 |
ZDV* | 3TC | TDF | 44 | 1.33 | 2.66 |
ZDV* | DLV | 3TC | 44 | 1.33 | 2.66 |
ZDV* | DLV | ddI | 44 | 1.33 | 2.66 |